Showing results (2171-2180 of 2,239) with videos related to
Sort By:
Pageof 224
Nature Communications|December 2, 2024
Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signalingWenji Piao, Long Wu, Yanbao Xiong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2017
Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung CancerAnna Li, Jin-Ji Yang, Xu-Chao Zhang, et al.Journal of Hematology & Oncology|April 17, 2020
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter studyChang Lu, Xiao-Rong Dong, Jun Zhao, et al.The Lancet. Respiratory Medicine|July 26, 2024
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 studyJin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, et al.Lung Cancer (Amsterdam, Netherlands)|November 28, 2017
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancerHai-Yan Tu, E-E Ke, Jin-Ji Yang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2016
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLCChristian Manegold, Anne-Marie C Dingemans, Jhanelle E Gray, et al.The Lancet. Oncology|August 17, 2013
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialYuankai Shi, Li Zhang, Xiaoqing Liu, et al.The Lancet. Oncology|January 16, 2015
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsJames Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, et al.Lung Cancer (Amsterdam, Netherlands)|January 30, 2022
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancerJianhua Chang, Yi-Long Wu, Shun Lu, et al.Cancer Discovery|May 11, 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung CancerJia-Tao Zhang, Si-Yang Liu, Wei Gao, et al.Pageof 224